Remus Stoica
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Remus Stoica has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Adrian-Marian Radu
Department of Radiotherapy, “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology, 022328 Bucharest, Romania
1 shared publication - Andrei Mircea Dicianu
Sf. Nectarie Oncology Center, 200347 Craiova, Romania
1 shared publication - Bogdan Chivu
Neolife Medical Center Bucharest, 077190 Bucharest, Romania
1 shared publication - Britta Weber
Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark
1 shared publication - Diana Mitrea
Department of Radiotherapy, “Prof. Dr. Alexandru Trestioreanu” Institute of Oncology, 022328 Bucharest, Romania
1 shared publication - Emmanuel Jouglar
Department of Radiation Oncology, Institut Curie, PSL University, Paris, France
1 shared publication
Latest Publications
- Open Access
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Reply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- 3 December 2025
- Published by Elsevier in Clinical and Translational Radiation Oncology
- Vol. 57, 101087
Open AccessReply to comment on impact of deep learning on CT-based organ-at-risk delineation for flank irradiation in paediatric renal tumours: A SIOP-RTSG radiotherapy committee
- Open Access
- 4 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 175
Risk of Myelopathy Following Second Local Treatment after Initial Irradiation of Spine Metastasis
Metastatic lesions of the spine occur in up to 40% of cancer patients and are a frequent source of pain and neurologic deficit due to cord compression. Palliative radiotherapy is the main first-intent local treatment in the form of single-fraction radiotherapy or fractionated courses. Reirradiation is a viable option for inoperable patients where spinal decompression is needed but with an increased risk of radiation-induced myelopathy (RM) and subsequent neurologic damage. This review summarizes reported data on local treatment options after initial irradiation in patients with relapsed spine metastasis and key dosimetric correlations between the risk of spinal cord injury and reirradiation technique, total dose, and time between treatments. The Linear Quadratic (LQ) model was used to convert all the published doses into biologically effective doses and normalize them to EQD2. For 3D radiotherapy, authors used cumulative doses from 55.2 Gy2/2 to 65.5 Gy2/2 EQD2 with no cases of RM mentioned. We found little evidence of RM after SBRT in the papers that met our criteria of inclusion, usually at the median reported dose to critical neural tissue around 93.5 Gy2/2. There is a lack of consistency in reporting the spinal cord dose, which leads to difficulty in pooling data.
- 4 January 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (2) , 175
Open AccessRisk of Myelopathy Following Second Local Treatment after Initial Irradiation of Spine Metastasis
Metastatic lesions of the spine occur in up to 40% of cancer patients and are a frequent source of pain and neurologic deficit due to cord compression. Palliative radiotherapy is the main first-intent local treatment in the form of single-fraction radiotherapy or fractionated courses. Reirradiation is a viable option for inoperable patients where spinal decompression is needed but with an increased risk of radiation-induced myelopathy (RM) and subsequent neurologic damage. This review summarizes reported data on local treatment options after initial irradiation in patients with relapsed spine metastasis and key dosimetric correlations between the risk of spinal cord injury and reirradiation technique, total dose, and time between treatments. The Linear Quadratic (LQ) model was used to convert all the published doses into biologically effective doses and normalize them to EQD2. For 3D radiotherapy, authors used cumulative doses from 55.2 Gy2/2 to 65.5 Gy2/2 EQD2 with no cases of RM mentioned. We found little evidence of RM after SBRT in the papers that met our criteria of inclusion, usually at the median reported dose to critical neural tissue around 93.5 Gy2/2. There is a lack of consistency in reporting the spinal cord dose, which leads to difficulty in pooling data.